Financial Performance - The company achieved operating revenue of ¥391,287,076.10, an increase of 18.91% compared to the previous year[4] - Net profit attributable to shareholders decreased by 11.72% to ¥70,454,856.57, while net profit excluding non-recurring gains and losses fell by 16.71% to ¥64,994,477.85[5] - Basic earnings per share decreased by 16.14% to ¥1.84, with a weighted average return on equity (excluding non-recurring items) of 37.60%[5] - Total assets increased by 183.37% to ¥611,410,752.81, and equity attributable to shareholders rose by 297.42% to ¥518,393,099.77[5] Market Expansion and Strategy - The company expanded both domestic and international markets, enhancing online and offline integration and increasing R&D investment for new product development[6] - The company is focusing on the development of new medical products and strengthening its sales channels[6] - The company plans to continue its strategy of expanding product offerings and enhancing brand promotion through online channels[6] Expenses and Profitability - The increase in R&D and sales expenses led to a rise in operating revenue but a decline in profit[6] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8] Capital Increase - The company completed a public offering of shares to unspecified qualified investors, resulting in an increase in net assets[7]
倍益康(870199) - 2022 Q4 - 年度业绩